Compare Novartis AG (NVS) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Riot Platforms Inc — how do they compare? Novartis AG trades at $153.01 (market cap $295.37B), while Riot Platforms Inc trades at $20.41 (market cap $7.59B). The key difference: Novartis AG is far larger — about 38.9× Riot Platforms Inc's market cap, and Novartis AG pays a 3.07% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals.
| NVS | RIOT | |
|---|---|---|
Market Cap | $295.37B | $7.59B |
Sector | Health | Technology |
52-Week High | $168.62 | $28.67 |
52-Week Low | $119.31 | $11.33 |
Enterprise Value | $336.69B | $8.00B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
RIOT Platforms trades at $20.90, up 7.73% in the last 24 hours, following the announcement of a landmark $9.1 billion, 20-year AI data center deal with Anthropic. Despite this positive news, the technical outlook remains bearish, and the company continues to report significant net losses, with a net income margin of -196.28% for 2026. Analyst sentiment is overwhelmingly positive, with a consensus price target of $33.40 representing substantial upside potential.
The stock presents a high-risk, high-reward opportunity. The transformative AI deal offers a clear long-term growth catalyst, but investors must weigh this against persistent unprofitability and negative cash flows. The key risk is the company's ability to execute its strategic pivot to AI infrastructure while managing its financial losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
